Current and historical daily PE Ratio for Novartis AG (
) from 1996 to Apr 27 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Novartis AG stock (NVSEF) PE ratio as of Apr 27 2024 is 13.9.
More Details
Novartis AG (NVSEF) PE Ratio (TTM) Chart
Novartis AG (NVSEF) PE Ratio (TTM) Historical Data
View and export this data going back to 1996. Start your Free Trial
Total 1215
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Novartis AG PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-28 | 13.1 | 2024-02-23 | 14.6 |
| 2024-04-26 | 13.1 | 2024-02-22 | 14.5 |
| 2024-04-25 | 13.1 | 2024-02-21 | 14.4 |
| 2024-04-24 | 13.1 | 2024-02-20 | 14.4 |
| 2024-04-23 | 13.1 | 2024-02-16 | 14.1 |
| 2024-04-22 | 13.0 | 2024-02-15 | 14.0 |
| 2024-04-19 | 12.3 | 2024-02-14 | 13.8 |
| 2024-04-18 | 12.3 | 2024-02-13 | 14.2 |
| 2024-04-17 | 12.8 | 2024-02-12 | 14.2 |
| 2024-04-16 | 12.8 | 2024-02-09 | 14.2 |
| 2024-04-15 | 12.8 | 2024-02-08 | 14.6 |
| 2024-04-12 | 12.8 | 2024-02-07 | 14.6 |
| 2024-04-11 | 12.8 | 2024-02-06 | 14.5 |
| 2024-04-10 | 12.8 | 2024-02-05 | 14.6 |
| 2024-04-09 | 13.1 | 2024-02-02 | 14.8 |
| 2024-04-08 | 12.9 | 2024-02-01 | 14.8 |
| 2024-04-05 | 12.9 | 2024-01-31 | 14.8 |
| 2024-04-04 | 12.9 | 2024-01-30 | 14.8 |
| 2024-04-03 | 12.6 | 2024-01-29 | 14.8 |
| 2024-04-02 | 13.0 | 2024-01-26 | 14.8 |
| 2024-04-01 | 13.2 | 2024-01-25 | 14.8 |
| 2024-03-28 | 13.2 | 2024-01-24 | 15.3 |
| 2024-03-27 | 13.5 | 2024-01-23 | 15.3 |
| 2024-03-26 | 13.5 | 2024-01-22 | 15.3 |
| 2024-03-25 | 13.5 | 2024-01-19 | 15.1 |
| 2024-03-22 | 13.6 | 2024-01-18 | 15.1 |
| 2024-03-21 | 13.6 | 2024-01-17 | 15.1 |
| 2024-03-20 | 13.3 | 2024-01-16 | 15.1 |
| 2024-03-19 | 13.7 | 2024-01-12 | 15.1 |
| 2024-03-18 | 14.1 | 2024-01-11 | 15.1 |
| 2024-03-15 | 14.1 | 2024-01-10 | 15.1 |
| 2024-03-14 | 14.1 | 2024-01-09 | 14.9 |
| 2024-03-13 | 13.8 | 2024-01-08 | 15.0 |
| 2024-03-12 | 13.8 | 2024-01-05 | 15.0 |
| 2024-03-11 | 13.9 | 2024-01-04 | 14.8 |
| 2024-03-08 | 14.4 | 2024-01-03 | 14.2 |
| 2024-03-07 | 14.4 | 2024-01-02 | 14.2 |
| 2024-03-06 | 14.4 | 2023-12-29 | 14.1 |
| 2024-03-05 | 14.4 | 2023-12-28 | 14.1 |
| 2024-03-04 | 14.4 | 2023-12-27 | 26.4 |
| 2024-03-01 | 14.4 | 2023-12-26 | 26.4 |
| 2024-02-29 | 14.2 | 2023-12-22 | 26.6 |
| 2024-02-28 | 14.8 | 2023-12-21 | 26.1 |
| 2024-02-27 | 14.8 | 2023-12-20 | 26.1 |
| 2024-02-26 | 14.8 | 2023-12-19 | 25.9 |
Novartis AG (NVSEF) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Novartis AG
NAICS : 325412
ISIN : CH0012005267
Share Class Description:
NVSEF: Registered SharesCompare
Compare
Traded in other countries / regions
NOVN.Switzerland0QLR.UKNVS.USANVS.ArgentinaNOTA.GermanyNVS N.MexicoN1VS34.Brazil IPO Date
1996-12-30Description
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers